FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)

The FDA’s R13 Scientific Conference Grant Program provides federal financial support for high-quality conferences and scientific meetings that align with the agency’s mission to protect and promote public health. These events, which may take the form of symposia, seminars, workshops, or other formal gatherings conducted in person or virtually, are intended to foster the exchange of information and advance research on topics relevant to FDA’s regulatory responsibilities. Funding is available to support activities that enhance scientific understanding and contribute to the development of public health policies, but applicants must ensure the conference occurs after the award is issued and before the event’s start date, as no award will be granted if it cannot be processed in time. Submission of an application does not guarantee funding, nor does it ensure the requested amount will be awarded. The program is open to eligible applicants seeking support for non-clinical trial scientific meetings, with the solicitation identified as FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed). The opportunity was forecasted on July 27, 2022, under the Department of Health and Human Services, and is managed by the Food and Drug Administration. Interested parties may contact Janelle Fundersburg, Grants Management Specialist, at the provided email or phone number for inquiries. There are no set-asides or NAICS codes associated with this solicitation, and performance locations are not restricted, allowing conferences to be held anywhere within the United States, including virtually.